Previous 10 | Next 10 |
ALLO-501 in Combination with ALLO-647 Based Lymphodepletion Regimen was Well Tolerated With No Dose-Limiting Toxicities or Evidence of Graft-vs-Host Disease Abstract Based on Data Cutoff in January 2020 Represents Limited Data Set of Nine Evaluable Patients Treated at Lower Dose (39mg) AL...
Investment thesis: As mentioned in our previous articles, Eonia Research focuses heavily on analyzing the underlying science of biotechs. After a prolonged search, we have found an intriguing biotech operating in the chimeric antigen receptor T-cell (CAR-T) space, Autolus therapeutics ( AUTL...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...
Allogene Therapeutics, Inc. (ALLO) Q1 2020 Earnings Conference Call May 6, 2020 08:30 ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President and Chief Executive Officer Rafael Amado - Executive Vice President, Research and Development an...
Image source: The Motley Fool. Allogene Therapeutics Inc (NASDAQ: ALLO) Q1 2020 Earnings Call May 06, 2020 , 8:30 a.m. ET Operator Continue reading
Allogene Therapeutics (NASDAQ: ALLO ): Q1 GAAP EPS of -$0.50 beats by $0.08 . More news on: Allogene Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Oral Presentation of Initial Results from the Phase 1 ALLO-501 ALPHA Trial in Relapsed/Refractory Non-Hodgkin Lymphoma at the Virtual American Society of Clinical Oncology (ASCO) Annual Meeting Phase 1 ALPHA2 Trial for ALLO-501A, the Next Generation anti-CD19 AlloCAR T™ Intend...
Oral Presentation is the First Data Readout from this Dose Escalation Study of ALLO-501, an Allogeneic Anti-CD19 CAR T Therapy ALPHA Study Utilizes ALLO-647 Administered as Part of its Differentiated Lymphodepletion Platform Phase 1 Study Continues Enrollment to Optimize Lymphodepletion...
Company Developed TurboCAR™ Technology Allows Cytokine Activation Signaling to be Engineered Selectively into CAR T Cells Preclinical Studies Provide Evidence That Cytokine Signaling Can Increase TurboCAR T Cell Activity While Avoiding Safety Risks of Exogenous Cytokine Admin...
Conference Call and Webcast Scheduled for 5:30 AM PT/8:30 AM ET SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therap...
News, Short Squeeze, Breakout and More Instantly...
Allogene Therapeutics Inc. Company Name:
ALLO Stock Symbol:
NASDAQ Market:
Allogene Therapeutics Inc. Website:
Patient Screening is Underway at Rocky Mountain Cancer Centers, Part of the US Oncology Network and Sarah Cannon Research Institute; Astera Cancer Care, Part of the OneOncology Network; and Norton Cancer Institute ALPHA3 Will be the First Pivotal Trial to Offer CAR T as Part of First Line (...
SOUTH SAN FRANCISCO, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced it will participate in th...
SOUTH SAN FRANCISCO, Calif., May 13, 2024 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced the pricing of an underwr...